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ABSTRACT 
The present study was undertaken to develop 
controlled release osmotic pump tablets of lamivudine a 
nucleoside reverse transcriptase inhibitor for the treatment 
of acquired immune deficiency syndrome (AIDS). The 
tablets were prepared by wet granulation method using 
controlled release polymer hydroxyl propyl methyl 
cellulose (HPMCE5 LV), MCC as a diluent, starch as binder 
and fructose as osmogen. The coating solution of core 
tablets was prepared by using cellulose acetate, poly 
ethylene glycol 400, 600, 4000, 6000 and acetone to a 
quantity sufficient with sorbitol for different batches. The 
prepared tablets were evaluated for pre compression 
parameters, post compression parameters, in vitro drug 
release study and scanning electron microscopy study. 
Among the prepared formulations LF4 batch show 97.78% 
drug release in 12h. The in vitro release kinetics were 
analyzed for different batches by different pharmacokinetic 
models such as zero order, first order, Higuchi, Korsmeye 
rPeppas and Hixon Crowell model. Short term stability 
study at 40±2ºC/75±5% RH for three months on the best 
formulation was performed showing no significant changes 
in thickness, hardness, friability, drug content and in vitro 
drug release.  
 
Keywords: AIDS, wet granulation, in vitro drug release, stability 
study 
  
INRODUCTION 
Controlled release dosage forms offer 
prolong drug release of active ingredients at a 
predetermined rate and a predetermined time 
(Presscott, 1989) Among various controlled 
drug delivery systems osmotic controlled drug 
delivery system (OCDDS) utilizes the principle 
of osmotic pressure for controlled delivery of 
active ingredients. The drug released from 
OCDDS is independent of pH and 
hydrodynamic condition of the body and 
agitation intensity (Kaushal et al., 2003). The 
present study is to develop controlled porosity 
osmotic pump (CPOP) tablets of lamivudine. 
The delivery system of the drug comprises a 
core with the drug surrounded by a 
semipermeable membrane (SPM) which is 
accomplished with different channeling agents 
of water soluble additives in the coating 
membrane. The core is coated with cellulose 
acetate containing in situ micro pore former 
sorbitol. Further for increasing drug release 
fructose of 355atm was chosen as osmotic agent 
to generate high osmotic pressure gradient in 
CPOP. When CPOP tablets placed in a 
biological system of fluid low levels of water 
soluble additives are leached from polymer 
materials which form a sponge like structure in 
the controlled porosity walls. The rate of drug 
delivery depends upon the factors (Zenter et al., 
1985) such as water permeability of the SPM, 
osmotic pressure of core formulation, thickness 
and the total area of the coating. 
Human immunodeficiency virus 
infection/acquired immune deficiency 
syndrome (HIV/AIDS) is a disease of the 
human immune system caused by infection 
with human immune deficiency virus. It is 
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called AIDS when a person infected with HIV 
has a CD4+ count of declines up to 
200cells/µL in the blood (Sahoo et al., 2017). 
AIDS is transmitted by via unprotected sexual 
intercourse, contaminated blood transfusions, 
hypodermic needles and from mother to child 
during pregnancy, delivery or breastfeeding. 
The prevention of HIV infection primarily 
through safe sex using condoms, needle 
exchange programs awareness required to 
control the spread of disease and may lead to a 
near normal life expectancy (Sahoo et al., 2015). 
The management of AIDS can be controlled by 
antiretroviral therapy, male circumcision, needle 
exchange program, use of diaphragms, topical 
protection, use of condoms and alternative 
medicine. 
Lamivudine is a synthetic nucleoside 
analogue and is phosphorylated intra cellularly 
to its active 5'-triphosphate metabolite, 
lamivudine triphosphate (L-TP). This 
nucleoside analogue is incorporated into viral 
DNA by HIV reverse transcriptase resulting in 
DNA chain termination (Richman, 2001). The 
present research aimed to design CPOP tablets 
of lamivudine by wet granulation method 
containing a dose of 300mg once daily. 
Lamivudine has a bioavailability of 86%, 
protein binding of 36% and the biological half-
life is between 5-7h. Hence it can be given to 
control the concentration of drug at the site of 
action. The main objective of the present            
study was to develop controlled porosity-         
based osmotically controlled release tablets of 
lamivudine 
 
MATERIALS AND METHODS 
Materials 
Lamivudine was obtained from Hetero 
Drugs Pvt. Ltd. India., fructose and mannitol 
were obtained from Qualigens Fine Chemicals, 
India. Cellulose acetate (CA) was obtained from 
Eastman Chemical Inc, Kingsport, TN. Sorbitol, 
magnesium stearate, talc, HPMCE5LV and 
polyethylene glycol (PEG) 400, 600, 4000, 6000 
were purchased from S.D. Fine Chemicals Ltd, 
Mumbai, India., Microcrystalline cellulose 
(MCC) and starch were purchased from Signet 
Pharma, Mumbai, India. All other solvents and 
reagents used were of analytical grade. 
 
 
Compatibility studies 
DSC 
Physical mixtures of drug and individual 
excipients in the ratio of 1:1 were taken and 
examined in DSC. Individual samples as well as 
a physical mixture of drug and excipients were 
weighed to about 5mg in DSC pan (Shimadzu 
DSC-50, Japan). The sample in the pan was 
scanned (Kumaravelrajan et al., 2011) in the 
temperature range of 50-300°C.The heating 
rate of 20°C min-1 was used and the thermogram 
obtained was reviewed for evidence of any 
interactions. Then the themograms were 
compared with pure samples versus optimized 
formulation. 
 
Preparation of lamivudine CPOP tablets 
The tablets were prepared by wet 
granulation technique (Sahoo et al., 2016). 
Accurately weighed quantities of ingredients 
(Table Ia) were passed through sieve No. 30. 
Lubricant (magnesium stearate), a glidant (talc) 
were passed through sieve No. 80. The ingre-
dients were manually blended homogenously in 
a mortar by way of geometric dilution without 
the addition of except lubricant and glidant. 
The mixture was moistened with an aqueous 
solution and granulated through sieve No.30 
and dried in a hot air oven at 60ºC for 
sufficient time (3-4h). The dried granules were 
passed through sieve No.30 and blended with 
talc and magnesium stearate. The homogenous 
blend was then compressed into round tablets 
with standard concave punches using 10 station 
rotary compression machine (Minipress, 
Karnavati, India). 
 
Coating of core tablets 
Table Ib summarizes the components of 
the coating solution. The coatings of tablets were 
performed by spray pan coating (Sahoo et al., 
2012) in a perforated pan (GAC-205, Gansons 
Ltd, Mumbai, India). Initially tablets were pre 
heated by passing hot air through the tablet bed 
and by rotating at a lower speed of  5-8rpm. 
The coating process was started with a rotation 
speed of 10-12 rpm. The spray rate and 
atomizing air pressure were 4-6mL/min and 
1.75 kg/cm2 respectively. Inlet and outlet air 
temperature were 50ºC and 40ºC respectively, 
coated tablets were dried at 50ºC for 12h. 
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Evaluation of CPOP tablets 
Pre compression parameters of CPOP 
granules (Sahoo et al.,2015) 
Angle of repose ( ) 
The flow property of granules was 
determined by measuring the angle of repose 
where the granules were allowed to flow 
through funnel freely onto the clean surface. 
The funnel was fixed at such a height that 
bottom tip of the funnel should not touch apex 
of the heap of granules. The angle of repose is 
calculated using the following equation:  
 
tan =h/r ………………………………... (1) 
 =tan-1(h/r)……………………………….(2) 
 
Where   is the angle of repose, h is the 
height of heap in cm and r is the radius of the 
circular support (cone) in cm. According to the 
specifications the angle of repose value less 
than 25ºC indicates excellent flow whereas 
angle greater than 40ºC indicates poor flow. 
 
Bulk density (еbulk) 
Bulk density is determined by pouring 
the granules into a graduated cylinder of bulk 
density apparatus (Sisco, India). The bulk 
volume (Vbulk) and mass (m) of the granules are 
determined. The bulk density is calculated by 
using the following formula. 
 
еbulk  
 
      
………………………………(3) 
 
Tapped density (еtap) 
The measuring cylinder containing a 
known mass of granules blend is tapped 1000 
times for a fixed time in tap density tester 
(Sisco, India). The minimum volume occupied 
in the cylinder (Vtap) and mass of the granules 
(m) are measured. The tapped density is 
measured by using the following formula. 
 
еtap 
 
    
……..………………………….. (4) 
 
Compressibility index (Carr’s index) 
The compressibility index determines the 
flow property characteristics (Patel et al., 2012) 
of granules developed by Carr. The Carr’s index 
can be calculated by the following formula. 
 
% Carr’s index =
           
     
  100….…....(5) 
 
Where etap is the tapped density of granules and 
ebulk is the bulk density of granules.  
According to the specifications the 
Carr’s index values between 5-15 indicates 
excellent flow whereas between 12-16 indicates 
good flow. Values between 18-21 indicate fair 
passable whereas between 23-35 indicates poor 
and values between 33-38 indicates very poor 
and greater than 40 indicates extremely poor. 
 
Hausner’s ratio (HR) 
Hausner’s ratio is used for the 
determination of flow properties of granules. 
Table Ia. Composition of lamivudine CPOP tablets 
 
Formulation 
code 
LM 
(mg) 
MCC 
(mg) 
Starch(
mg) 
HPMC 
E5LV(mg) 
Fructose
(mg) 
Magnesium 
stearate 
(mg) 
Talc 
(mg) 
Total wt. 
(mg) 
LF1 300 190 25 100 25 5 5 650 
LF2 300 165 25 100 50 5 5 650 
LF3 300 140 25 100 75 5 5 650 
LF4 300 115 25 100 100 5 5 650 
 
Table I b. Coating composition for CPOP tablets 
 
Formulation 
code 
CA 
(g) 
PEG 400 
(g) 
PEG 600 
(g) 
PEG 
4000(g) 
PEG 6000 
(g) 
Sorbitol 
(g) 
Acetone 
(mL) 
LF1 6 2 0 0 0 0 300 
LF2 6 0 2 0 0 0.4 300 
LF3 6 0 0 2 0 0.8 300 
LF4 6 0 0 0 2 1.2 300 
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The Hausner’s ratio can be calculated by the 
following formula 
 
HR=
     
     
……………………….…………(6) 
 
According to specifications values less 
than 1.25 indicate good flow (= 20% of Carr’s 
index) whereas greater than 1.25 indicates poor 
flow (=33% of Carr’s index). 
 
Post compression parameters of CPOP 
tablets (Sahoo et al.,2015) 
Thickness 
The thickness of individual tablets is 
measured by using Vernier caliper (Absolute 
digimatic, Mitutoyo Corp. Japan) which gives 
the accurate measurement of thickness in mm. 
The limit of the thickness deviation of each 
tablet is 5%. 
 
Coat thickness 
After dissolution the film was isolated 
from the tablets and dried at 40ºC for 
1hr.Thickness was measured by using electronic 
digital calipers (Absolute digimatic, Mitutoyo 
Corp. Japan) and mean values were taken. 
 
Hardness test 
The hardness of tablets can be 
determined by using Monsanto hardness tester 
(Sisco, India) and measured in terms of kg/cm2.  
 
Friability test 
Friability of tablets was performed in a 
Roche friabilator (Sisco, India). Ten tablets 
(Edavalath et al., 2011) were initially weighed 
(Winitial) together and then placed in the 
chamber. The friabilator was operated for 25 
revolutions for 4minsand the tablets are then 
dusted and reweighed (Wfinal). The percentage 
of friability was calculated using the following 
equation. 
 
%Friability=   (   
      
        
)      ....(7)                                                                
 
Where, Winitial and Wfinal are the weight of the 
tablets before and after the test respectively.  
 
Weight variation test 
The weight variation test is done by 
weighing 20 tablets individually in weighing 
balance (Shimadzu, Japan) calculating the 
average weight (Maheswari et al., 2012) and 
comparing the individual tablet weights to the 
average. The percentage weight deviation was 
calculated and then compared with USP 
specifications. 
  
Uniformity of drug content test
 Ten tablets were weighed and powdered 
by mortar. Drug content (USP, 2003, Pragathi 
et al., 2015) for tablets was done by the assay 
method. An accurately weighed equivalent 
weighed quantity of powdered tablet was 
dissolved in 0.1N HCl using magnetic stirrer 
(Ricon, Hyderabad, India) in a volumetric flask 
for 24h. The solution was filtered through 
Whatman filter paper No.1 and analyzed 
spctrophotometrically at 280nm (Shimadzu 
UV-1800, Japan). 
 
Diameter of tablet 
The diameter of individual tablets is 
measured by using vernier caliper (Absolute 
digimatic, Mitutoyo Corp. Japan)in mm. 
 
In vitro dissolution studies 
In vitro dissolution test (Kanagale et al., 
2007) was carried out by using USP type II 
(paddle) apparatus at 75 rpm in 900mL of 
dissolution fluid of 0.1N HCl for first 2hours 
and phosphate buffer pH 6.8 from 3 to 12h 
maintained at 37±0.5ºC. At specified time 
intervals 5mL aliquot of the solution was 
withdrawn through 0.45-μm cellulose acetate 
filter from the dissolution apparatus (Sahoo et 
al., 2017) with the replacement of fresh fluid to 
dissolution medium. The filtered solution is 
diluted and analyzed spectrophotometrically at 
280nm for 0.1N HCl (pH 1.2) and 270nm for 
phosphate buffer pH 6.8. 
 
Mathematical modeling of in vitro drug 
release(IVDR)kinetics 
For the determination of the drug release 
kinetics (Sahoo et al., 2015) from the porous 
osmotic pump tablet, the in vitro release data 
were analyzed by zero order, first order, 
Higuchi, Korsmeyer and Peppas and Hixson-
Crowell equations. 
Zero order kinetics can be expressed by the 
equation 
 
Qt=Q0 K0t…………………………….….(8) 
 
Where 
Qt is the amount of drug dissolved in time t, Q0 
is the initial amount of drug in the solution and 
K0 is the zero order release constant. 
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First order kinetics can be expressed by 
the equation: 
 
Log C = log C0 K1t/2…………...………. (9) 
 
Where C0 is the initial concentration of the 
drug, C is the amount of drug remaining to be 
released in time t, K1 is the first order release 
constant.  
Higuchi’s classical diffusion equation 
(Higuchi, 1963) can be expressed as 
 
Q = KH √ t…………………………..….(10) 
 
Where Q is the amount of drug release in time 
t, KH is the Higuchi dissolution constant.  
Korsmeyer-Peppas model (KP Model) 
for the drug release (Korsmeyer et al., 1983) for 
this model is expressed as 
 
 
Log (Mt/M∞)  Log K n Log t…………(11) 
 
 
Where Mt is the amount of drug release at time 
t, M∞ is the amount of drug release after an 
infinite time, K is the release rate constant 
incorporating structural and geometric 
characteristics of the tablet and n is the release 
exponent indicative of mechanism of drug 
release.  
Hixson and Crowell model (Hixson, 
1931) is expressed by the equation 
 
W01/3  Wt1/3  κ t……………………….(12) 
 
Where W0 is the initial amount of drug in the 
pharmaceutical dosage form, Wt is remaining 
amount of drug in the pharmaceutical          
dosage form at time t and κ is proportionality        
constant incorporating the surface volume 
relation.  
 
Effect of osmogen concentration  
To check the effect of osmogen (Shah et 
al., 2013) concentration on drug release 
formulations were prepared with the different 
concentration of osmotic agents (Sahoo et al., 
2017) and all other parameters of tablet kept 
constant. The drug release was compared with 
the different osmogen concentration of 
formulated batches by using USP-II dissolution 
apparatus. 
 
Effect of pore former concentration  
Different concentrations of pore former 
(Dasankoppa et al., 2013) are used in SPM 
formation.  In   order  to  compare   the  effect               
of different concentrations of pore formers            
in vitro release profiles as well as a number of 
formation of micro pores are compared. 
 
Effect of coating thickness  
The tablet is kept in 900mL of 
dissolution fluid 0.1N HCl for first 2h and next 
followed by 3 to 12h in phosphate buffer pH 
6.8 of USP type II dissolution apparatus at 75 
rpm and maintaining the temperature 37±0.50C 
of dissolution media to check the effect of 
membrane thickness (Sahoo et al., 2017). The 
sample 5mL was withdrawn through 0.45-μm 
cellulose acetate filter at different time intervals 
replaced with fresh medium and analyzed in 
UV-Visible spectrophotometer. 
 
Effect of osmotic pressure  
The effect on osmotic pressure (Rani et 
al., 2004) on the optimized formulation was 
studied in media of different osmotic pressure 
and the release profile with varying osmotic 
pressure is compared. To increase the osmotic 
pressure of the release media mannitol (Sahoo 
et al., 2017) was added to produce 30 atm, 60 
atm and 90 atm respectively. 
 
Effect of pH  
In order to study the effect of pH of 
release medium in the drug release of optimized 
formulation, the in vitro release study was 
carried in dissolution media having different 
pH media (Patel et al., 2012). Dissolution can be 
carried in 900mL of 0.1 N HCl (pH 1.2), pH 
6.8 and phosphate buffer pH 7.4 in USP type II 
dissolution apparatus at 75rpm with 
maintaining the temperature at 37±0.5°C. The 
sample (5mL) was withdrawn at predetermined 
intervals and analyzed after filtration through 
0.45-μm cellulose acetate filter.  
 
Effect of agitation intensity  
The drug release of optimized 
formulation was subjected to dissolution at 
various rotation speeds (Verma et al., 2004) to 
demonstrate the effect of agitation intensity. 
Dissolution was carried out in USP-II (Paddle) 
at 50, 100 and 150rpm. The samples were 
withdrawn at predetermined intervals through 
0.45-μm cellulose acetate filter and analyzed by 
UV-Visible spectrophotometer.  
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Scanning electron microscopy study  
In order to observe the mechanism of 
drug release and surface morphology (Rao et al., 
2009) from the developed formulations surface  
coated tablets before and after dissolution 
studies was examined using scanning electron 
microscope (Leica, Bensheim, Switzerland).  
 
Accelerated stability studies  
The formulation was subjected to 
accelerated stability studies (Sharma et al., 2014) 
as per ICH (The International Conference of 
Harmonization) guidelines. The packed tablets 
in air tight container were placed in stability 
chambers (Thermo lab Scientific equipment 
Pvt. Ltd., Mumbai, India) maintained at 
40±2ºC, 75±5% RH for 3 months. Tablets 
were periodically removed and evaluated for 
physical characteristics, drug content, in vitro 
drug release etc. 
 
RESULTS ANS DISCUSSION 
DSC thermograms 
DSC thermo gram showed an 
endothermic peak at 162.2ºC which is the 
corresponding melting point of drug        
(Figure 1a). DSC thermo gram showed an 
endothermic peak at 161.2ºC in the LF4 
formulation (Figure 1b). From the above            
DSC studies it  was observed that the 
formulation is thermodynamically stable. No 
shifting of peaks from endothermic to 
exothermic was also noticed. Hence physical 
mixture showed that there was compatibility 
with the drug. 
 
Pre compression parameters 
The angle of repose of pre-compression 
blends of various batches was in the range of 
25.01±0.12 to 28.78±0.14. The bulk density of 
pre-compression blends was found to be in the 
range of 0.524±0.14 to 0.528±0.12g/mL, 
tapped density in the range of 0.558±0.06 to 
0.571±0.12g/mL, the Carr’s index values were 
in the range of 5.73±0.05 to 8.05±0.14, and 
Hausner’s ratio values were ranges of 
1.06±0.03 to 1.08±0.11. So the results of pre 
compression parameters such as angle of 
repose, bulk density, tapped density, Carr’s 
index, and Hausner’s ratio indicated that the 
dry granules of all the formulations of 
lamivudine showed excellent flow properties 
which favor easy manufacturing of CPOP 
tablets under study (Table IIa). 
 
 
Figure 1a. DSC thermogram of lamivudine 
 
 
 
Figure 1b. DSC thermogram of LF4 
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Post compression parameters 
The thickness of formulated tablets was 
found to be in the range of 3.503±0.02 to  
3.571±0.02mm, coat thickness in the range of 
100.3±2.4 to 251.1±3.2µm, the hardness values 
were in the range of 7.6±0.12 to 8.1±0.04kg/ 
cm2, the friability values were in range of 
0.11±0.13 to 0.19±0.04, average weight of tablet 
was in the range of 649.09±1.03 to 651.08±1.04 
mg, drug content of tablet was in the range of 
98.69±1.03 to 99.47±1.25 and diameter of tablets 
values were ranges of 11.98±0.06 to 12.29±0.03 
mm. Post compression parameters of all the 
formulation of lamivudine showed satisfied 
results according to the Pharmacopoeias 
specifications (Table IIb). 
 
In vitro drug release study 
The in vitro drug release characteristics 
were studied in 900mLof 0.1N HCl (pH1.2) for 
a period of the first 2h and 3 to 12h in 
phosphate buffer pH 6.8 using USP type II 
dissolution apparatus (Paddle type). The 
cumulative percentage drug release for LF1, 
LF2, LF3 and LF4 were 90.54, 91.26, 92.43  
and 97.78% respectively of lamivudine at the 
end of 12h. It was observed that the drug 
release is more in LF4 batch as it contains 
100mg of polymer and 100mg of fructose. 
Hence it was confirmed that the drug release 
depends upon osmotic pressure of osmogen 
(Figure 2). 
 
Table IIa. Pre compression parameters of CPOP granules 
 
Formulation 
code 
Angle of 
repose 
(degree)a ± 
S.D 
Bulk density 
(g/mL)a± 
S.D 
Tapped 
density 
(g/mL)a± 
S.D 
Carr’s 
Index 
(%)a± S.D 
Hausner’sRatioa± 
S.D 
 
LF1 28.78±0.14 0.528±0.12 0.562±0.11 6.05±0.14 1.06±0.09 
LF2 27.82±0.12 0.524±0.14 0.567±0.12 7.58±0.12 1.08±0.11 
LF3 26.19±0.11 0.525±0.11 0.571±0.12 8.05±0.14 1.08±0.09 
LF4 25.01±0.12 0.526±0.04 0.558±0.06 5.73±0.05 1.06±0.03 
 
N.B.-All values are expressed as mean  S.D, a n = 3 
 
Table IIb. Post compression parameters of lamivudine CPOP tablets 
 
Formulation 
code 
Thickness 
(mm)a ± 
S.D 
Coat 
thickness 
(µm)a ± S.D 
Hardness 
(kg/cm2)a 
±S.D 
% 
Friability 
(%)b ± 
S.D 
Average 
wt.of tablet 
(mg)b± S.D 
%Drug 
content(%)a 
± S.D 
Diameter 
(mm)a ± 
S.D 
LF1 3.571±0.02 251.1±3.2 7.6±0.12 0.17±0.05 649.09±1.03 99.219±1.15 12.13±0.05 
LF2 3.567±0.03 200.8±3.1 7.9±0.01 0.19±0.04 651.08±1.04 98.69±1.03 11.98±0.06 
LF3 3.509±0.01 150.5±2.6 8.0±0.02 0.12±0.12 650.07±1.03 98.958±1.06 12.29±0.03 
LF4 3.503±0.02 100.3±2.4 8.1±0.04 0.11±0.13 650.04±1.1 99.47±1.25 12.2±0.07 
 
N.B.-All values are expressed as mean  S.D, a n = 10, b n = 20 
 
Table III. Fitting of IVDR data in various mathematical models 
 
Models Zero order First order Higuchi Korsmeyer-Peppas Hixson-Crowell 
Batches R2 K0 R12 K1 RH2 KH RK2 Kkp n R2 Ks 
LF1 0.946 6.324 0.927 0.1658 0.972 24.77 0.941 26.061 0.458 0.961 0.181 
LF2 0.920 6.229 0.950 0.1727 0.986 24.90 0.963 29.922 0.419 0.971 0.184 
LF3 0.903 6.274 0.954 0.1888 0.987 25.33 0.964 32.885 0.394 0.973 0.195 
LF4 0.886 6.446 0.884 0.2487 0.982 26.21 0.953 36.728 0.368 0.956 0.229 
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Figure 2. In vitro release profiles showing 
lamivudine release from various fabricated 
formulations LF1-LF4 
 
IVDR kinetics 
From the kinetic it is observed that LF1 
follows non-Fickian transport mechanism and 
LF2, LF3 and LF4 show Fickian diffusion 
mechanism. The regression values of LF1 to 
LF4 for zero order were 0.946, 0.920, 0.903 and 
0.886 respectively. The regression values of 
LF1 to LF4 for first order were found to be 
0.927, 0.950, 0.954 and 0.884 respectively. All 
the formulations showed to be best expressed 
by Higuchi equation as the plots showed high 
linearity with regression values closer to unity. 
The optimized formulation LF4 is showing 
highest regression values (R2) in Higuchi model 
than zero order and first order. Hence the drug 
release follows Higuchi kinetics. The n value 
for optimized formulation is 0.368 (n 0.45). 
Hence it follows Fickian diffusion mechanism 
(Table III). 
 
Effect of osmogene concentration 
It is observed that osmogene enhances 
the drug release of drug and thus had a direct 
effect on drug release. The concentrations of 
osmogen were 25, 50, 75 and 100mg/tablet for 
LF1, LF2, LF3 and LF4 respectively. The 
cumulative percentage drug release for LF1, 
LF2, LF3 and LF4 were 90.54, 91.26, 92.43 and 
97.78% respectively of lamivudine at the end of 
12h. It was observed that the drug release is 
more in LF4 batch comparing to other batches 
due to more concentration of osmotic agent 
(Figure 2).  
 
Effect of pore former 
To study the effect of pore forming 
agent core formulations of lamivudine were 
coated with varying coating compositions of 
pore forming agent containing 0%, 6.6%, 
13.3% and 20% w/w of CA of sorbitol for 
LF1, LF2, LF3 and LF4 respectively. The drug 
release order for LF1 to LF4 batch is 
LF4>LF3>LF2>LF1. The optimized 
lamivudine CPOP tablets LF4 contain fructose 
100mg/tab and pore former concentration 
20% w/w of CA of sorbitol releases drug 
97.78% up to end of 12h. It is clearly evident 
that the level of sorbitol had a direct effect on 
drug release. As the level of pore former 
increases the membrane becomes more porous 
after coming contact with aqueous 
environment resulting in faster drug release. 
Statistical analysis (‘t’-test) of drug release data 
gives t value of 0.03 for an LF4 formulation 
which is much less compared to the table value 
of 2.353 (p<0.05). Hence it can be concluded 
that osmogen concentration as well as porogen 
concentration both have a direct relation to 
drug release of lamivudine (Figure 2). 
 
Effect of membrane thickness 
The coating thickness for LF1, LF2, LF3 
and LF4 were 251.1, 200.8, 150.5 and 100.3µM 
respectively. The drug release is highest 
(97.78%) at the end of 12h in LF4 because the 
thickness of coat is less. Similarly, the drug 
release is minimum at the end of 12h in 
LF1(90.54%) as the thickness of coat is more. 
It is clearly evident that drug release decreases 
with increase in a coating thickness of the semi 
permeable membrane Release profile of 
lamivudine from these formulations (Figure 2). 
 
 
 
Figure 3. In vitro release profiles showing 
lamivudine release from best LF4 in different 
osmotic pressures 
 
Effect of osmotic pressure 
The results of release studies of 
optimized formulation in media of different 
osmotic pressure indicated that the drug release 
is highly dependent on the osmotic pressure of 
the release media. The release was inversely 
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related to the osmotic pressure of release 
media. This finding confirms that the 
mechanism of drug release is by osmotic 
pressure. The drug release for LF4 was found 
to be 89.36% for 30atm, 79.24% for 60atm and 
70.98% for 90atm respectively (Figure 3). 
 
Effect of pH 
The optimized formulation LF4 was 
subjected to in vitro drug release studies in 
buffers with different pH media like 0.1N HCl 
(pH 1.2), phosphate buffer pH 6.8 and 
phosphate buffer pH7.4 in USP type II 
dissolution apparatus in 75rpm. The drug 
release of optimized formulation was observed 
in 0.1N HCl (pH 1.2) for drug release, it was 
found that the drug release was nearly same for 
the end of 11h. But at the end of 12h the drug 
release was same with optimized formulation 
97.78%. The drug release of the LF4 
formulation was observed in phosphate buffer 
pH 6.8 for drug release, it was found that the 
drug release was nearly same for the end of 
11h. But at the end of 12h the drug release was 
same with optimized formulation 97.78%. The 
drug release of the LF4 formulation was 
observed in phosphate buffer pH 7.4 for drug 
release, it was found that the drug release was 
nearly same for the end of 11h. But at the end 
of 12h the drug release was same with 
optimized formulation 97.78%. It is observed 
that there is no significant difference in the 
release profile, demonstrating that the 
developed formulation shows pH independent 
release (Figure 4). 
 
 
 
Figure 4. In vitro dissolution study of best 
formulation LF4 in various pH media 
 
Effect of agitation intensity 
The optimized formulation of the LF4 
batch was carried out in USP dissolution 
apparatus type-II at varying rotational speeds 
(50,100 and 150rpm). The drug releases of the 
optimized formulation were observed in 50, 
100 and 150rpm for drug release, it was found 
that the drug release was nearly same for the 
end of 11h. But at the end of 12h the drug 
release was same with optimized formulation 
97.78%. It shows that the release of lamivudine 
from CPOP is independent of agitation 
intensity. Hence it is expected that the release 
from the developed formulation will be 
independent of the hydrodynamic conditions of 
the absorption site (Figure 5). 
 
 
 
Figure 5. In vitro dissolution study of best 
formulation LF4 in various agitation speeds 
 
SEM analysis 
SEM study indicates before dissolution 
fewer pores were found in the coating 
membrane. But after dissolution comparatively 
more numbers of pores were found in the 
membrane might be due to leaching or removal 
of the entrapped drug from the formulation as 
well as the presence of pore forming agent 
sorbitol in the formulation (Figure 6 a and 6 b). 
 
 
 
Figure 6a. SEM image of LF4 before 
dissolution, 6b. SEM image of  LF4 after 
dissolution 
 
Stability studies 
From short term stability studies of 
optimized formulation LF4, it was confirmed 
that there was no significance changes in 
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physical appearance, thickness, hardness, 
friability, weight variation and drug content and 
% drug release.  
 
CONCLUSION 
Lamivudine CPOP tablets were 
successfully developed. Out of several 
formulations LF4 containing 100mg of fructose 
per core tablet, 100mg of HPMC E5LV and 1.2 
gm of sorbitol in SPM as pore former was 
successfully complied with the rate of drug 
release of CPOP tablets. Thus LF4 can provide 
more prolong, control and pH independent 
drug release and expected to perform 
therapeutically better with improved patient 
compliance. 
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